|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3132333435363738394041...6768» |
- Bexxar (iodine I 131 tositumomab) / GSK
Trial completion: Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 6, 2014
P1, N=38, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed
- Bexxar (iodine I 131 tositumomab) / GSK
Trial completion, Enrollment change: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 6, 2014
P2, N=112, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=140 --> 112
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment open: Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=40, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | N=140 --> 112 Not yet recruiting --> Recruiting
- | Calsed (amrubicin) / Sumitomo Pharma, BMS
Enrollment closed, Trial primary completion date, Combination therapy: Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 5, 2014
P1/2, N=42, Active, not recruiting, Sponsor: Michaela Liedtke
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Oct 2014
- Folotyn (pralatrexate) / Aurobindo
Enrollment closed, Trial primary completion date, Combination therapy: Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM (clinicaltrials.gov) - Aug 5, 2014
P1, N=28, Active, not recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Oct 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Feb 2014
- lenalidomide / Generic mfg., azacitidine / Generic mfg.
Enrollment closed, IO biomarker, Immunomodulating: Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=19, Active, not recruiting, Sponsor: Virginia Commonwealth University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Feb 2014 Recruiting --> Active, not recruiting
- bortezomib / Generic mfg., dexamethasone / Generic mfg., zoledronic acid / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy (clinicaltrials.gov) - Aug 5, 2014
P2, N=17, Completed, Sponsor: University of Athens
Recruiting --> Active, not recruiting Recruiting --> Completed | N=62 --> 17 | Trial primary completion date: Dec 2014 --> May 2013
- ||| Trial completion: Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=114, Completed, Sponsor: Denver Health and Hospital Authority
Recruiting --> Completed | N=62 --> 17 | Trial primary completion date: Dec 2014 --> May 2013 Recruiting --> Completed
- | lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
New P2 trial: Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM) (clinicaltrials.gov) - Aug 1, 2014
P2, N=80, Recruiting, Sponsor: Fondazione Neoplasie Sangue Onlus
- bortezomib / Generic mfg.
Trial primary completion date: Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients (clinicaltrials.gov) - Jul 30, 2014
P2, N=20, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Completed Trial primary completion date: Dec 2013 --> Jul 2015
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
New P1/2 trial: Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST) (clinicaltrials.gov) - Jul 30, 2014
P1/2, N=50, Not yet recruiting, Sponsor: Sunnybrook Health Sciences Centre
- NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion, Observational data: Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=36, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2013 --> Jul 2015 Active, not recruiting --> Completed
- Farydak (panobinostat) / Secura Bio
Combination therapy: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=0, Available, Sponsor: Novartis Pharmaceuticals
- || cyclosporin A microemulsion / Generic mfg.
New P3 trial: A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia ?ITP? (clinicaltrials.gov) - Jul 30, 2014
P3, N=120, Recruiting, Sponsor: Shandong University
- ||||| Votrient (pazopanib) / Novartis, BeiGene
New P2 trial: Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia (clinicaltrials.gov) - Jul 30, 2014
P2, N=60, Not yet recruiting, Sponsor: GlaxoSmithKline
- CYAD-01 / Celdara Medical, Celyad Oncology
New P1 trial, Metastases: Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) - Jul 30, 2014
P1, N=21, Not yet recruiting, Sponsor: Celdara Medical, LLC
- ||||| Nuwiq (simoctocog alfa) / Octapharma
Enrollment closed, Enrollment change: NuPreviq: Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - Jul 30, 2014
P3, N=66, Active, not recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=55 --> 66
- Benlysta (belimumab) / GSK
Enrollment change, Trial withdrawal, Trial primary completion date: A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. (clinicaltrials.gov) - Jul 24, 2014
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | N=55 --> 66 N=48 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2013 --> Apr 2015
- Clinical: HEPS: An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=66, Active, not recruiting, Sponsor: The Hospital for Sick Children
- Clinical: HOLISTIC: Multidisciplinary Evaluation of Patients With Hemophilia (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=50, Enrolling by invitation, Sponsor: Universidad de Murcia
- Clinical: Manual Therapy in Haemophilic Arthropathy of the Knee (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=21, Completed, Sponsor: Universidad Católica San Antonio de Murcia
- ||| lenalidomide / Generic mfg.
Enrollment closed, Immunomodulating: CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Jul 23, 2014
P2, N=82, Active, not recruiting, Sponsor: David Seldin, MD
N=48 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2013 --> Apr 2015 Completed --> Active, not recruiting
- dexamethasone / Generic mfg., pomalidomide / Generic mfg.
P1 data: Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 16, 2014
P1, N=42, Not yet recruiting, Sponsor: New Mexico Cancer Care Alliance
Completed --> Active, not recruiting Initiation date: Apr 2014 --> Jul 2014 | Trial primary completion date: Aug 2017 --> Jul 2016
- Clinical: Educational Needs of Patients With Systemic Vasculitis (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=386, Completed, Sponsor: University of South Florida
- |||| Ojjaara (momelotinib) / GSK
Trial completion, IO biomarker: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Jul 15, 2014
P1/2, N=61, Completed, Sponsor: Gilead Sciences
Initiation date: Apr 2014 --> Jul 2014 | Trial primary completion date: Aug 2017 --> Jul 2016 Active, not recruiting --> Completed
- |||| Ojjaara (momelotinib) / GSK
Trial completion: Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) (clinicaltrials.gov) - Jul 15, 2014
P2, N=120, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Combination therapy: MM_LEN_DEX_CY: Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2014
P1/2, N=40, Completed, Sponsor: Gesellschaft fur Medizinische Innovation
Active, not recruiting --> Completed Recruiting --> Completed | N=70 --> 40
- DI Leu16 IL-2 / Provenance, Alopexx, EMD Serono, Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 15, 2014
P1, N=9, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Completed | N=70 --> 40 Active, not recruiting --> Completed | N=36 --> 9 | Trial primary completion date: Sep 2016 --> Jul 2014
- lenalidomide / Generic mfg.
Trial primary completion date: UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma (clinicaltrials.gov) - Jul 14, 2014
P3, N=300, Recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed | N=36 --> 9 | Trial primary completion date: Sep 2016 --> Jul 2014 Trial primary completion date: Apr 2014 --> Apr 2015
- || carfilzomib / Generic mfg.
Clinical: UARK 2009-32 Compassionate Use Study of Carfilzomib (clinicaltrials.gov) - Jul 14, 2014
P=N/A, N=140, Active, not recruiting, Sponsor: University of Arkansas
Trial primary completion date: Apr 2014 --> Apr 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- tabalumab (LY2127399) / Eli Lilly
Enrollment closed, Combination therapy: Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma (clinicaltrials.gov) - Jul 14, 2014
P1, N=10, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2013 --> Dec 2014 Recruiting --> Active, not recruiting
- Trial termination: A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma (clinicaltrials.gov) - Jul 12, 2014
P2, N=20, Terminated, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; due to lack of funding
- Trial completion, Trial primary completion date: Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy (clinicaltrials.gov) - Jul 12, 2014
P4, N=70, Completed, Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Active, not recruiting --> Terminated; due to lack of funding Recruiting --> Completed | Trial primary completion date: Mar 2011 --> Mar 2012
- || bortezomib / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date: Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=110, Recruiting, Sponsor: Oncotherapeutics
Recruiting --> Completed | Trial primary completion date: Mar 2011 --> Mar 2012 Trial primary completion date: Mar 2014 --> Sep 2014
- bortezomib / Generic mfg., melphalan / Generic mfg., carfilzomib / Generic mfg.
Clinical: Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments (clinicaltrials.gov) - Jul 12, 2014
P1/2, N=45, Active, not recruiting, Sponsor: Oncotherapeutics
Trial primary completion date: Mar 2014 --> Sep 2014 Trial primary completion date: Mar 2014 --> Sep 2014
- Zolinza (vorinostat) / Merck (MSD)
Clinical: Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma (clinicaltrials.gov) - Jul 12, 2014
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2014 --> Sep 2014 N=75 --> 0 | Not yet recruiting --> Withdrawn
- cyclophosphamide / Generic mfg., pomalidomide / Generic mfg.
Clinical: Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide (clinicaltrials.gov) - Jul 12, 2014
P2, N=60, Recruiting, Sponsor: University Hospital Tuebingen
N=75 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- ||| Darzalex IV (daratumumab) / J&J
Clinical: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma (clinicaltrials.gov) - Jul 12, 2014
P1/2, N=112, Active, not recruiting, Sponsor: Genmab
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Biostate (factor VIII/von Willebrand factor) / CSL Behring
Trial completion, Enrollment change: Study of Biostate (clinicaltrials.gov) - Jul 12, 2014
P3, N=35, Completed, Sponsor: CSL Behring
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=24 --> 35
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial primary completion date: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Jul 10, 2014
P1, N=22, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed | N=24 --> 35 Trial primary completion date: Mar 2015 --> Dec 2015
- RG7598 / Roche
Trial primary completion date: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 10, 2014
P1, N=39, Completed, Sponsor: Genentech
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Apr 2015 --> Apr 2014
- | RG7598 / Roche
Trial completion: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 10, 2014
P1, N=39, Completed, Sponsor: Genentech
Trial primary completion date: Apr 2015 --> Apr 2014 Recruiting --> Completed
- |||| Trial primary completion date, Monotherapy: Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma (clinicaltrials.gov) - Jul 8, 2014
P3, N=646, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Trial primary completion date: Dec 2014 --> May 2014
- | nintedanib / Generic mfg.
New P1 trial, IO biomarker: An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 8, 2014
P1, N=17, Completed, Sponsor: Boehringer Ingelheim
- | Trial completion, HEOR: IMAJEM: Imaging Young Myeloma (IMAgerie JEune My (clinicaltrials.gov) - Jul 8, 2014
P3, N=152, Completed, Sponsor: Nantes University Hospital
Trial primary completion date: Dec 2014 --> May 2014 Active, not recruiting --> Completed
- ||||||| Trial completion, Trial primary completion date, Monotherapy: Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma (clinicaltrials.gov) - Jul 8, 2014
P3, N=646, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2014
- || RG7598 / Roche
Trial completion, Enrollment change, Trial primary completion date: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 6, 2014
P1, N=76, Recruiting, Sponsor: Genentech
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2014 N=45 --> 76 | Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Apr 2014
- long-acting sequence-modified recombinant factor VIIa (BAY 866150) / Bayer
Trial termination: A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 (clinicaltrials.gov) - Jul 5, 2014
P2/3, N=10, Terminated, Sponsor: Bayer
N=45 --> 76 | Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Apr 2014 Active, not recruiting --> Terminated
- long-acting sequence-modified recombinant factor VIIa (BAY 866150) / Bayer
Enrollment change, Trial termination: A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 (clinicaltrials.gov) - Jul 5, 2014
P2/3, N=10, Terminated, Sponsor: Bayer
Active, not recruiting --> Terminated N=65 --> 10 | Completed --> Terminated
- || Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial primary completion date: OPTIMS: Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=100, Recruiting, Sponsor: Bayer
N=65 --> 10 | Completed --> Terminated Trial primary completion date: Jun 2014 --> Sep 2014